The company has not filed an annual or quarterly report since its Q3 FY2019 10-Q, filed Nov 14, 2019. Its latest SEC filing is a 15-12B from Jan 7, 2020.
10-Q for Q3 FY2019, filed Nov 14, 2019
The sections below describe the company as of the FY2018 annual report.
Develops personalized cell and gene therapies made from patients’ skin cells for diseases affecting the skin and connective tissue.
10-K for FY2018, filed Mar 27, 2019We are an autologous cell and gene therapy company focused on translating personalized biologics into medical breakthroughs for diseases…View ↗
We are focused on discovering and developing localized therapies for diseases affecting the skin and connective tissue, where there are…View ↗
Our proprietary autologous fibroblast technology is the foundation for creating personalized biologics for diseases of the skin and…View ↗
10-Q for Q3 FY2019, filed Nov 15, 2019
−$7.2MView ↗
8-K, filed Dec 13, 2019
Upon consummation of the Merger, at the Effective Time, each share of common stock of the Company issued and outstanding immediately prior…View ↗
8-K, filed Sep 13, 2019
Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each…View ↗
Narrowed disease focus
The older report included vocal cord scarring and diseases of the joints alongside skin and connective tissue conditions; the latest report focuses on skin and connective tissue, with arthritis remaining in research.
10-K for FY2015, filed Mar 10, 2016 10-K for FY2018, filed Mar 27, 2019We are focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints to improve…View ↗
Our most advanced development program is azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. We…View ↗
In collaboration with Intrexon Corporation ("Intrexon"), we have two gene-therapy product candidates in pre-clinical development and a…View ↗
Earlier product left the pipeline
The older report described an FDA-approved fibroblast treatment for wrinkles and its study for vocal cord scarring; the latest report centers on gene therapy candidates for skin and connective tissue conditions.
10-K for FY2015, filed Mar 10, 2016 10-K for FY2018, filed Mar 27, 2019
Competes with Abeona Therapeutics, Krystal Biotech, Cytori Therapeutics, and miRagen Therapeutics
10-K for FY2018, filed Mar 27, 2019FCX-007 for RDEB. Our product candidate FCX-007 is being developed for the treatment of RDEB. Current treatments for RDEB, which include…View ↗
Loading...
